Sign in to continue:

Thursday, March 5th, 2026

Changyou International Group Limited Announces Board Meeting to Approve 2025 Final Results and Dividend on March 25, 2026 1

Changyou International Group Limited Announces Board Meeting to Consider Final Results and Dividend

Changyou International Group Limited Schedules Board Meeting to Approve 2025 Final Results and Dividend

Hong Kong, 5 March 2026 – Changyou International Group Limited (“the Company”, Stock Code: 1039) has announced that its Board of Directors will convene a critical meeting on Wednesday, 25 March 2026. The meeting will be held at Office Room 45, Unit 405-414, Level 4, Core E, Cyberport 3, 100 Cyberport Road, Pok Fu Lam, Hong Kong.

Key Points for Investors

  • Board Meeting Date Set: The Board will meet on 25 March 2026. This is a scheduled, significant event for the company.
  • Approval of Final Results: The Board will review and approve the final financial results of Changyou International Group Limited and its subsidiaries for the year ended 31 December 2025. The publication of these results will provide the market with a comprehensive update on the company’s performance for the fiscal year.
  • Consideration of Final Dividend: The Board will also consider the payment of a final dividend, if any. The declaration or recommendation of a dividend is typically a key event for shareholders and can have a direct impact on the company’s share price.

Details Investors Should Note

  • Potential Price Sensitivity:
    • The announcement and subsequent release of the final results for 2025 could significantly influence investor sentiment and share price, depending on the company’s financial performance relative to market expectations.
    • Dividend Decision: The Board’s deliberation on the final dividend is also highly price-sensitive. A dividend declaration could provide a positive catalyst for the stock, while the absence of a dividend or a lower-than-expected payout may have a negative impact.
  • Board Composition:
    • The current Board comprises:
      • Executive Directors: Mr. Cheng Jerome, Mr. Sun Jun
      • Non-Executive Directors: Ms. Hu Qing, Ms. Liu Jingyan
      • Independent Non-Executive Directors: Mr. Wong Chi Keung, Mr. Ip Wai Lun William, Mr. Chan Chi Keung Alan
    • The Company Secretary is Mr. Chan Chi Keung.

What to Watch For

  • Investors should closely monitor the outcome of the Board meeting on 25 March 2026 for:
    • The release of the audited final results for the year ended 31 December 2025
    • Any announcement regarding the payment of a final dividend
    • Management’s commentary on the company’s performance and outlook, which is often included in the results announcement

Conclusion: The upcoming Board meeting and its resolutions regarding the final results and dividend are material events for Changyou International Group Limited. Investors and shareholders are advised to stay alert for the official publication of the results and any dividend decision, as these could have an immediate and significant impact on the company’s share price.


Disclaimer: The above article is for informational purposes only and does not constitute investment advice. Investors should conduct their own research and consider their own circumstances or consult with a professional advisor before making any investment decisions. The company’s actual results, dividend decisions, and share price may be affected by various factors, including but not limited to market conditions, regulatory developments, and other unforeseen events.


View CHANGYOU INT GP Historical chart here



CK Life Sciences Announces Board Meeting to Approve 2025 Annual Results and Final Dividend on March 17, 2026 1

CK Life Sciences International (Holdings) Inc. Announces Upcoming Board Meeting for Annual Results and Dividend Consideration CK Life Sciences International (Holdings) Inc. Announces Upcoming Board Meeting Key Points Investors Should Know Board Meeting Scheduled:...

Ferretti International Holding S.p.A. Purchases Shares in Ferretti S.p.A. – Disclosure Under Hong Kong Takeovers Code 1

Key Points for Investors Large Share Purchase: On 3 March 2026, Ferretti International Holding S.p.A. purchased 240,063 shares of Ferretti S.p.A. Purchase Price: The shares were acquired at a price of \$33.2410 per share....

CSPC Pharmaceutical Group Receives Clinical Trial Approval in China for Emicizumab Injection Hemlibra Biosimilar for Hemophilia A 1

CSPC Pharmaceutical Group: Emicizumab Injection Clinical Trial Approval in China CSPC Pharmaceutical Group Limited Announces Clinical Trial Approval for Emicizumab Injection (SYS6053) in China CSPC Pharmaceutical Group Limited (Stock Code: 1093) has released a...

   Ad